Related references
Note: Only part of the references are listed.Blood Triglyceride Monitoring With Smartphone as Electrochemical Analyzer for Cardiovascular Disease Prevention
Jian Wang et al.
IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS (2019)
Extreme hypertriglyceridemia: Genetic diversity, pancreatitis, pregnancy, and prevalence
Vadzim Chyzhyk et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease
Brian A. Ference et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
The Chylomicronemia Syndrome Is Most Often Multifactorial A Narrative Review of Causes and Treatment
Alan Chait et al.
ANNALS OF INTERNAL MEDICINE (2019)
Targeting RNA to lower triglycerides: long strides from short molecules
Arman Qamar et al.
EUROPEAN HEART JOURNAL (2019)
Conservative management in hypertriglyceridemia-associated pancreatitis
A. J. Berberich et al.
JOURNAL OF INTERNAL MEDICINE (2019)
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
J. L. Witztum et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Low-Grade Inflammation in the Association between Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis: A Study of More Than 115000 Individuals from the General Population
Signe E. J. Hansen et al.
CLINICAL CHEMISTRY (2019)
Severe hypertriglyceridemia is primarily polygenic
Jacqueline S. Dron et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol
Scott M. Grundy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
JoAnn E. Manson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Unmet need for primary prevention in individuals with hypertriglyceridaemia not eligible for statin therapy according to European Society of Cardiology/European Atherosclerosis Society guidelines: a contemporary population-based study
Christian M. Madsen et al.
EUROPEAN HEART JOURNAL (2018)
The Atherogenic Dyslipidemia Complex and Novel Approaches to Cardiovascular Disease Prevention in Diabetes
Priska Stahel et al.
CANADIAN JOURNAL OF CARDIOLOGY (2018)
Effects of Pemafibrate, a Novel Selective PPAR alpha Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
Eiichi Araki et al.
DIABETES CARE (2018)
Angiopoietin-like protein 4: A therapeutic target for triglycerides and coronary disease?
David S. Olshan et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Characterizing familial chylomicronemia syndrome: Baseline data of the APPROACH study
Dirk J. Blom et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Clinical and biochemical features of different molecular etiologies of familial chylomicronemia
Robert A. Hegele et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
Om P. Ganda et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks Meta-analysis of 10 Trials Involving 77 917 Individuals
Theingi Aung et al.
JAMA CARDIOLOGY (2018)
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
Stephen J. Nicholls et al.
CLINICAL CARDIOLOGY (2018)
Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
Aruna D. Pradhan et al.
AMERICAN HEART JOURNAL (2018)
The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study
Marcello Arca et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2018)
Very-Low-Density Lipoprotein- Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III
Raimund Pechlaner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
ANGPTL3 Deficiency and Protection Against Coronary Artery Disease
Nathan O. Stitziel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Severe hypertriglyceridemia in Norway: prevalence, clinical and genetic characteristics
Kjetil Retterstol et al.
LIPIDS IN HEALTH AND DISEASE (2017)
Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity
Danish Saleheen et al.
NATURE (2017)
ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
Daniel Gaudet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Mark J. Graham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
F. E. Dewey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
Stanley T. Crooke et al.
NUCLEIC ACID THERAPEUTICS (2017)
Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism
Anna Wolska et al.
ATHEROSCLEROSIS (2017)
Changes in mean serum lipids among adults in Germany: results from National Health Surveys 1997-99 and 2008-11
Julia Truthmann et al.
BMC PUBLIC HEALTH (2016)
Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
Changting Xiao et al.
DIABETES (2016)
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
Andres Digenio et al.
DIABETES CARE (2016)
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2016)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano et al.
EUROPEAN HEART JOURNAL (2016)
ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors
Philip L. S. M. Gordts et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Multidimensional regulation of lipoprotein lipase: impact on biochemical and cardiovascular phenotypes
Robert A. Hegele
JOURNAL OF LIPID RESEARCH (2016)
Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism
Ilenia Minicocci et al.
JOURNAL OF LIPID RESEARCH (2016)
Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results
Xiaohong Yang et al.
JOURNAL OF LIPID RESEARCH (2016)
Interpretation of the evidence for the efficacy and safety of statin therapy
Rory Collins et al.
LANCET (2016)
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
Nathan O. Stitziel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Frederick F. Dewey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis
Simon B. Pedersen et al.
JAMA INTERNAL MEDICINE (2016)
Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?
Geesje M. Dallinga-Thie et al.
CURRENT CARDIOLOGY REPORTS (2016)
Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptides
Toshihiro Sakurai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Novel therapeutics in hypertriglyceridemia
Steven E. Gryn et al.
CURRENT OPINION IN LIPIDOLOGY (2015)
Hypertriglyceridemia in the Genomic Era: A New Paradigm
Gary F. Lewis et al.
ENDOCRINE REVIEWS (2015)
The risk of cardiovascular events with increased apolipoprotein CIII: A systematic review and meta-analysis
Moritz C. Wyler von Ballmoos et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects
Charles D. Meyers et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion
Yan Wang et al.
JOURNAL OF LIPID RESEARCH (2015)
ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys
Viktoria Gusarova et al.
JOURNAL OF LIPID RESEARCH (2015)
Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins
Gregory G. Schwartz et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome
Charles Daniel Meyers et al.
LIPIDS IN HEALTH AND DISEASE (2015)
Chylomicronaemia-current diagnosis and future therapies
Amanda J. Brahm et al.
NATURE REVIEWS ENDOCRINOLOGY (2015)
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Daniel Gaudet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Apolipoprotein C-III: From Pathophysiology to Pharmacology
Giuseppe Danilo Norata et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction
Ron Do et al.
NATURE (2015)
Risk prediction with triglycerides in patients with stable coronary disease on statin treatment
Christian Werner et al.
CLINICAL RESEARCH IN CARDIOLOGY (2014)
Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial
H. Denison et al.
DIABETES OBESITY & METABOLISM (2014)
Current knowledge of hypertriglyceridemic pancreatitis
Pedro Valdivielso et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2014)
Plasmapheresis as treatment for hyperlipidemic pancreatitis
A. Ramirez-Bueno et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2014)
Triglycerides and cardiovascular disease
Borge G. Nordestgaard et al.
LANCET (2014)
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Anders Berg Jorgensen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting APOC3 in the Familial Chylomicronemia Syndrome
Daniel Gaudet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
Jacy Crosby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management
Robert A. Hegele et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Apolipoprotein C-III Going Back to the Future for a Lipid Drug Target
Murray W. Huff et al.
CIRCULATION RESEARCH (2013)
The Role of Fibrate Treatment in Dyslipidemia: An Overview
Niki Katsiki et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial
D. Gaudet et al.
GENE THERAPY (2013)
Postprandial lipemia and cardiovascular disease risk: Interrelationships between dietary, physiological and genetic determinants
Kim G. Jackson et al.
ATHEROSCLEROSIS (2012)
Gene therapy for lipoprotein lipase deficiency
Daniel Gaudet et al.
CURRENT OPINION IN LIPIDOLOGY (2012)
Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production
Zemin Yao et al.
CURRENT OPINION IN LIPIDOLOGY (2012)
Triglyceride levels and apolipoprotein E polymorphism in patients with acute pancreatitis
Radka Ivanova et al.
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL (2012)
Effect of Alipogene Tiparvovec (AAV1-LPLS447X) on Postprandial Chylomicron Metabolism in Lipoprotein Lipase-Deficient Patients
Andre C. Carpentier et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study
Supna Sandhu et al.
LIPIDS IN HEALTH AND DISEASE (2011)
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Min Jun et al.
LANCET (2010)
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Kiran Musunuru et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effects of a Plant-Based High-Carbohydrate/High-Fiber Diet Versus High-Monounsaturated Fat/Low-Carbohydrate Diet on Postprandial Lipids in Type 2 Diabetic Patients
Claudia De Natale et al.
DIABETES CARE (2009)
Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events
Samia Mora et al.
CIRCULATION (2008)
A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
Toni I. Pollin et al.
SCIENCE (2008)
Association of cystic fibrosis transmembrane conductance regulator (CFTR) mutation/variant/haplotype and tumor necrosis factor (TNF) promoter polymorphism in hyperlipidemic pancreatitis
Yu-Ting Chang et al.
CLINICAL CHEMISTRY (2008)
Triglycerides and the risk of coronary heart disease - 10 158 incident cases among 262 525 participants in 29 Western prospective studies
Nadeem Sarwar et al.
CIRCULATION (2007)
Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL
Stefano Romeo et al.
NATURE GENETICS (2007)
AAV1-LPL S447X gene therapy reduces hypertriglyceridemia in apoE2 knock in mice
Jaap Rip et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2006)
Share Paper
